Payment overview · 2025
General Payments
$32.48
2 reported records · 2 companies
Healthcare provider profile · identity verified
Michael J Freeman, DO
Allopathic & Osteopathic Physicians|Family Medicine · WALTON, NY · NPI 1396743407
Verified facts
What the public records show
CMS Open Payments records show Michael J Freeman, DO received $32.48 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.69 | 54.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.79 | 45.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $32.48 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 108 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 84 |
| Gabapentin | Gabapentin | 281 | 75 |
| Lisinopril | Lisinopril | 258 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 70 |
| Omeprazole | Omeprazole | 239 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 217 | 67 |
| Metformin Hcl | Metformin Hcl | 209 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 61 |
| Prednisone | Prednisone | 174 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 42 |
| Simvastatin | Simvastatin | 158 | 48 |
| Trulicity | Dulaglutide | 157 | 23 |
| Eliquis | Apixaban | 147 | 50 |
| Losartan Potassium | Losartan Potassium | 146 | 57 |
| Furosemide | Furosemide | 138 | 50 |
| Meloxicam | Meloxicam | 137 | 37 |
| Montelukast Sodium | Montelukast Sodium | 132 | 45 |
| Carvedilol | Carvedilol | 130 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 41 |
| Alprazolam | Alprazolam | 116 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 112 | 21 |
| Baclofen | Baclofen | 98 | 28 |
| Tramadol Hcl | Tramadol Hcl | 95 | 23 |
| Allopurinol | Allopurinol | 92 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 92 | 25 |
| Sertraline Hcl | Sertraline Hcl | 91 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 20 |
| Ramipril | Ramipril | 79 | 30 |
| Atenolol | Atenolol | 76 | 20 |
| Trazodone Hcl | Trazodone Hcl | 73 | 25 |
| Buspirone Hcl | Buspirone Hcl | 71 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Ozempic | Semaglutide | 70 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Potassium Chloride | Potassium Chloride | 67 | 26 |
| Famotidine | Famotidine | 66 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 17 |
| Lorazepam | Lorazepam | 65 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 14 |
| Celecoxib | Celecoxib | 61 | 16 |
| Azithromycin | Azithromycin | 60 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 18 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 56 | 16 |
| Finasteride | Finasteride | 56 | 16 |
| Mirtazapine | Mirtazapine | 55 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 18 |
| Synthroid | Levothyroxine Sodium | 52 | 18 |
| Diazepam | Diazepam | 50 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 28 |
| Sucralfate | Sucralfate | 45 | 11 |
| Amoxicillin | Amoxicillin | 44 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 17 |
| Spironolactone | Spironolactone | 42 | 18 |
| Warfarin Sodium | Warfarin Sodium | 42 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 17 |
| Meclizine Hcl | Meclizine Hcl | 38 | suppressed |
| Nystatin | Nystatin | 38 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Naproxen | Naproxen | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 13 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 11 |
| Nitroglycerin | Nitroglycerin | 29 | 14 |
| Ibuprofen | Ibuprofen | 27 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Valsartan | Valsartan | 27 | 11 |
| Entresto | Sacubitril/Valsartan | 26 | 14 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 19 |
| Farxiga | Dapagliflozin Propanediol | 24 | 11 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Cartia Xt | Diltiazem Hcl | 22 | suppressed |
| Lactulose | Lactulose | 22 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Mesalamine Dr | Mesalamine | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Fentanyl | Fentanyl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32.48 · 2 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, Ozempic, PREVNAR 20, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error